MAIA Biotechnology enrolls first patient in expansion of phase 2 clinical trial for ateganosine in advanced non-small cell lung cancer: Chicago Friday, July 11, 2025, 12:00 Hrs [I ...

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II ...

CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...

In recent years, growing needs for advanced security and traffic management have significantly heightened the prominence of the visible-infrared person re-identification community (VI-ReID), garnering ...